Clinical trials: Glucose Metabolism Disorders
Gestational Diabetes, Diabetes, Gestational
Metabolic Analysis for Treatment Choice in Gestational Diabetes Mellitus
Gestational diabetes (GDM) is a significant clinical and public health burden, affecting over 400,000 pregnant women in the United States each year.
- Conditions
- Gestational Diabetes, Diabetes, Gestational, Pregnancy in Diabetes
- Trial name
- MATCh-GDM (NCT03029702)
- Testing
- Insulin, Glyburide, Metformin
- Where
- United States
- Volunteers
- 54 people
- Sponsor
- Maisa N. Feghali, MD
Diabetes Mellitus, Type 2
A Research Study to See How Semaglutide Works Compared to Placebo in People With Type 2 Diabetes and Chronic Kidney Disease
The researchers are doing this study to see if semaglutide can slow down the growth and worsening of chronic kidney disease in people with type 2 diabetes.
- Trial name
- FLOW (NCT03819153)
- Testing
- Semaglutide
- Where
- 413 sites in United States, Argentina and 26 more
- Volunteers
- 3,533 people
- Sponsor
- Novo Nordisk A/S
Type 2 Diabetes Mellitus
A Single-Dose Crossover Study of MK0893 in Patients With Type 2 Diabetes (0893-019 AM4)(COMPLETED)
This study will assess the effect of combined treatment with MK0893 plus propranolol versus placebo plus propranolol on hypoglycemia.
- Trial name
- NCT00902161
- Testing
- MK0893, Propranolol Hydrochloride (HCL)
- Volunteers
- 22 people
- Sponsor
- Merck Sharp & Dohme LLC
Diabetes Type 1
A Study of LY900014 and Insulin Lispro With an External Continuous Subcutaneous Insulin Infusion System in Adult Participants With Type 1 Diabetes
The purpose of this study is to evaluate the compatibility and safety of LY900014 and insulin lispro with an external continuous subcutaneous insulin infusion system in adult participants with type 1 diabetes.
- Trial name
- PRONTO-Pump (NCT03433677)
- Testing
- LY900014, Insulin lispro
- Where
- 5 sites in United States, Spain
- Volunteers
- 49 people
- Sponsor
- Eli Lilly and Company
HIV-Associated Lipodystrophy Syndrome, Insulin Resistance
Growth Hormone and/or Rosiglitazone for HIV-Associated Increased Abdominal Fat and Insulin Resistance
The purpose of the study is to determine if the combination of recombinant human growth hormone plus rosiglitazone (an insulin-sensitizing drug) is safe and more effective than either drug alone (or no active therapy) for the…
- Conditions
- HIV-Associated Lipodystrophy Syndrome, Insulin Resistance, HIV Infections, Metabolic Syndrome X
- Trial name
- NCT00130286
- Testing
- Rosiglitazone, Recombinant human growth hormone + rosiglitazone
- Where
- 4 sites in United States
- Volunteers
- 77 people
- Sponsor
- Weill Medical College of Cornell University
Diabetes Mellitus, Diabetes Mellitus, Type 2
A Virtual Cardiometabolic Health Program for African Immigrants: The Afro-DPP Program
A pilot study titled "A Virtual Cardiometabolic Health Program for African Immigrants (The Afro-DPP Program) will be conducted to address the cardiometabolic of community-dwelling African immigrants who have multiple…
- Conditions
- Diabetes Mellitus, Diabetes Mellitus, Type 2, PreDiabetes, Hypertension
- Trial name
- NCT05144737
- Testing
- The Diabetes Prevention Program
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- Johns Hopkins University
Diabetes Mellitus, Type 2
A Comparative Study of LY900014 With Insulin Lispro (Humalog) in Participants With Type 2 Diabetes Mellitus (T2DM)
The purpose of this study is to evaluate a new formulation of insulin lispro, LY900014, which is a drug that lowers blood sugar.
- Trial name
- NCT03341312
- Testing
- LY900014, Insulin Lispro
- Where
- 2 sites in Germany
- Volunteers
- 36 people
- Sponsor
- Eli Lilly and Company
Diabetes, Cardiovascular Risk Factor
Diabetes Prevention Translation: the Healthy Lifestyle Project
The Diabetes Prevention Program (DPP), a large research study conducted in the United States, found that lifestyle intervention was effective in lowering risk for development of type 2 diabetes.
- Trial name
- NCT01050205
- Testing
- Current Intervention, Delayed Intervention
- Where
- United States
- Volunteers
- 223 people
- Sponsor
- University of Pittsburgh
Type2Diabetes, Diabetes
QBSafe: a Randomized Trial of a Novel Intervention to Improve Care for People Living With Type 2 Diabetes.
Glycemic control is often the main indicator of successful diabetes care, but a singular focus on glycemic control may lead to patients' overall health and wellbeing being overlooked or undervalued.
- Trial name
- NCT05553912
- Testing
- QBSafe
- Where
- United States
- Volunteers
- 154 people
- Sponsor
- Yale University
Type 2 Diabetes Mellitus
A Clinical Study to Evaluate Renal Hemodynamic Responses to Aliskiren in Patients With Type 2 Diabetes Mellitus
The study objective was to assess the effect of single and multiple doses of aliskiren on renal plasma flow, glomerular filtration rate and to compare the effects of single and multiple doses of aliskiren versus captopril or…
- Trial name
- NCT00660309
- Testing
- Aliskiren, Irbesartan, Captopril
- Where
- United States
- Volunteers
- 45 people
- Sponsor
- Novartis
Diabetes Mellitus, Type 2
Safety and Efficacy of Linagliptin (BI 1356) as Monotherapy or in Combination in Type 2 DM
The objective of the current study is to investigate the safety and tolerability of BI 1356 (5 mg / once daily) given for 78 weeks in different modalities of treatment.
- Trial name
- NCT00736099
- Testing
- linagliptine 5 mg, linagliptine 5 mg and pioglitazone 30 mg
- Where
- 232 sites in United States, Argentina and 30 more
- Volunteers
- 2,122 people
- Sponsor
- Boehringer Ingelheim
PreDiabetes, Weight Loss
The National Diabetes Prevention Program in Rural Communities
The purpose of this pilot trial is to compare feasibility and effectiveness of remote delivery (social media or video conferencing) of the National Diabetes Prevention Program (N-DPP) to adults in rural communities.
- Conditions
- PreDiabetes, Weight Loss, Lifestyle Risk Reduction
- Trial name
- Rural NDPP (NCT05387434)
- Testing
- Diabetes Prevention Program-Remote (DPP-R), Diabetes Prevention Program-Facebook (DPP-FB)
- Where
- United States
- Volunteers
- 31 people
- Sponsor
- University of Kansas Medical Center
Heart Defects, Congenital, Hyperglycemia
SPECS: Safe Pediatric Euglycemia in Cardiac Surgery
Critically ill children, including children undergoing heart surgery, commonly develop elevated blood glucose (also known as "blood sugar") levels during their illness, which can lead to poor health outcomes and an increased risk…
- Trial name
- SPECS (NCT00443599)
- Testing
- Insulin, Usual Care
- Where
- 2 sites in United States
- Volunteers
- 989 people
- Sponsor
- Boston Children's Hospital
Type 2 Diabetes Mellitus
Physical Activity and Participation
The purpose of the study is to investigate if the investigators can improve physical activity and social participation level among Veterans with diabetes.
- Trial name
- NCT02268916
- Testing
- Counseling, Usual education
- Where
- United States
- Volunteers
- 104 people
- Sponsor
- VA Office of Research and Development
Type 2 Diabetes Mellitus
Efficacy and Safety of Teneligliptin in Chinese Patients With Type 2 Diabetes Mellitus
This study is designed as a prospective, multi-centre, parallel group, double-blind randomized, placebo-controlled, phase 3 clinical study to evaluate the efficacy and safety of MP-513 (Teneligliptin).
- Trial name
- NCT02916706
- Testing
- Teneligliptin 20mg
- Where
- China
- Volunteers
- 254 people
- Sponsor
- Tanabe Pharma Corporation
Schizophrenia, Insulin Resistance
Effectiveness of Aripiprazole for Improving Side Effects of Clozapine in the Treatment of People With Schizophrenia
This study will evaluate the effects of combination treatment with aripiprazole and clozapine on insulin resistance, blood fat levels, and weight gain in people diagnosed with schizophrenia.
- Trial name
- NCT00345033
- Testing
- Aripiprazole
- Where
- United States
- Volunteers
- 38 people
- Sponsor
- Massachusetts General Hospital
Diabetes Mellitus
Study of Alogliptin Combined With Pioglitazone in Subjects With Type 2 Diabetes Mellitus
The purpose of this study is to evaluate the efficacy and safety of alogliptin, once daily (QD), combined with pioglitazone in adults with type 2 diabetes mellitus
- Trial name
- NCT00286494
- Testing
- Alogliptin and pioglitazone, Pioglitazone
- Where
- 77 sites in United States, Argentina and 12 more
- Volunteers
- 493 people
- Sponsor
- Takeda
Diabetes Mellitus, Type 2, Endothelial Dysfunction
Cardiovascular Effects of Chronic Sildenafil in Men With Type 2 Diabetes
Type 2 Diabetes Mellitus (T2DM) represents a model of endothelial dysfunction, where chronic nitric oxide deprivation, hyperglycaemia and hyperinsulinemia and fibrogenic mediators lead to cardiovascular remodelling associated…
- Trial name
- CECSID (NCT00692237)
- Testing
- Sildenafil
- Where
- Italy
- Volunteers
- 59 people
- Sponsor
- University of Roma La Sapienza
Diabetes, Diabetes Mellitus, Type 2
Efficacy and Safety of Semaglutide Once-weekly Versus Placebo as add-on to Basal Insulin Alone or Basal Insulin in Combination With Metformin in Subjects With Type 2 Diabetes
This trial is conducted in Asia, Europe and the United States of America (USA). The aim of the trial is to investigate efficacy and safety of semaglutide once weekly versus placebo as add-on to basal insulin alone or basal…
- Trial name
- SUSTAIN™ 5 (NCT02305381)
- Testing
- semaglutide
- Where
- 99 sites in United States, Germany and 4 more
- Volunteers
- 397 people
- Sponsor
- Novo Nordisk A/S
Diabetic Gastroparesis
Continuous Glucose Monitoring and Insulin Pump Therapy in Diabetic Gastroparesis
A pilot study to assess the safety, feasibility, and potential (uncontrolled) efficacy of continuous glucose monitoring (CGMS) in conjunction with an insulin pump to improve glycemic control for treatment of type 1 and type 2…
- Trial name
- GLUMIT-DG (NCT01030341)
- Testing
- CGMS and insulin pump
- Where
- 7 sites in United States
- Volunteers
- 45 people
- Sponsor
- Johns Hopkins Bloomberg School of Public Health
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.